Aviv Philip Goncharov

Dr. Aviv Philip Goncharov

Palacký University, Olomouc, Olomoucký Kraj, Czech Republic
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
AGAviv Philip Goncharov
Aviv Philip Goncharov
NVNino Vashakidze
Nino Vashakidze
GKGvantsa Kharaishvili
Gvantsa Kharaishvili
Epithelial-mesenchymal transition (EMT) is a crucial and fundamental mechanism in many cellular processes, beginning with embryogenesis via tissue remodulation and wound healing, and plays a vital role in tumorigenesis and metastasis formation. EMT is a complex process that involves many transcription factors and genes that enable the tumor cell to leave the primary location, invade the basement membrane, and send metastasis to other tissues. Moreover, it may help the tumor avoid the immune system and establish radioresistance and chemoresistance. It may also change the normal microenvironment, thus promoting other key factors for tumor survival, such as hypoxia-induced factor-1 (HIF-1) and promoting neoangiogenesis. In this review, we will focus mainly on the role of EMT in benign prostate disease and especially in the process of establishment of malignant prostate tumors, their invasiveness, and aggressive behavior. We will discuss relevant study methods for EMT evaluation and possible clinical implications. We will also introduce clinical trials conducted according to CONSORT 2010 that try to harness EMT properties in the form of circulating tumor cells to predict aggressive patterns of prostate cancer. This review will provide the most up-to-date information to establish a keen understanding of the cellular and microenvironmental processes for developing novel treatment lines by modifying or blocking the pathways.

15 May 2025 in Annals of Medicine
Verified
Journal Article
Open access
AGAviv Philip Goncharov
Aviv Philip Goncharov
CEConstantinos Dicusari Elissaiou
Constantinos Dicusari Elissaiou
EFElad Ben Aharon Farzalla
Elad Ben Aharon Farzalla
GAGiorgi Akhvlediani
Giorgi Akhvlediani
NVNino Vashakidze
Nino Vashakidze
GKGvantsa Kharaishvili
Gvantsa Kharaishvili
From tumorigenesis to the establishment of local or metastatic high-grade tumours, an integral part of the cellular lifespan relies on various signalling pathways. Particular pathways that allow cells to proliferate by creating a network of new blood vessels have been documented, whereas other pathways are primarily involved with a migration to distant body parts, partially through the process of epithelial-mesenchymal transition (EMT). This review will discuss the different signalling pathways, such as TGF-β, Cripto-1, Wnt pathways, Hedgehog, Notch and NF-κB pathways, and how they promote tumour initiation and progression by influencing diverse cellular processes and EMT in general and in benign and malignant prostate tumours. This review will discuss only the critical pathways. Therefore, many other types of signalling pathways which are related to prostate cancer will not be discussed. Possibilities for further investigation will be mentioned, as many underlying mechanisms involved in these pathways have potential as targets in future tumour therapy. This review will also introduce some novel clinical trials relating to the inhibition of signalling pathways and their clinical outcomes.

28 September 2026 in Discover Oncology
Verified
Journal Article
Open access
PDF file
MSMartina Spisarova
Martina Spisarova
AGAviv Philip Goncharov
Aviv Philip Goncharov
GKGvantsa Kharaishvili
Gvantsa Kharaishvili
DSDaniela Skanderova
Daniela Skanderova
JOJakub Olejko
Jakub Olejko
BMBohuslav Melichar
Bohuslav Melichar
TFEB-amplified renal cell carcinoma (RCC) is an exceptionally rare and aggressive molecular subtype of kidney cancer, recently recognised in the updated WHO classification. Its diagnosis is complicated by histological heterogeneity and overlapping features with other RCC variants, often requiring advanced molecular techniques such as FISH or genomic profiling for confirmation. Unlike more common RCC subtypes, TFEB-amplified RCC lacks standardised treatment protocols, and no approved targeted therapies currently exist. While surgical resection remains the cornerstone of management, systemic therapy options- such as tyrosine kinase inhibitors and immune checkpoint inhibitors- have shown variable efficacy in isolated case reports. The rarity of this entity poses significant challenges to evidence-based treatment development and precision oncology, underscoring the urgent need for collaborative research. This case report describes an asymptomatic 67-year-old patient with TFEB-amplified RCC in the right kidney who underwent robotic-assisted right partial nephrectomy and, 6 months later, on CT, was diagnosed with local recurrence with inferior vena cava invasion and involvement of lymph nodes. The patient received perioperative treatment with ipilimumab and nivolumab, achieving an excellent response with no further signs of disease recurrence for the last 29 months since systemic treatment initiation. These findings highlight the potential relevance of PD-L1 assessment in guiding immunotherapy decisions for this exceptionally rare histopathological subtype.